Journal Mobile Options
Table of Contents
Vol. 26, No. 1, 2006
Issue release date: December 2005
Neuroepidemiology 2006;26:16–22

Change in Cognitive Function in Alzheimer’s Disease in African-American and White Persons

Barnes L.L. · Wilson R.S. · Li Y. · Gilley D.W. · Bennett D.A. · Evans D.A.
aRush Alzheimer’s Disease Center, bRush Institute for Healthy Aging, and Departments of cNeurological Sciences, dInternal Medicine and eBehavioral Sciences, Rush University Medical Center, Chicago, Ill., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Few studies have examined the association of race with change in cognitive function in Alzheimer’s disease (AD). We studied the rate of decline in global and specific measures of cognitive function in a cohort of 410 older African-Americans and whites with clinically diagnosed AD. Persons were examined annually for an average of 3.5 years, and follow-up participation among survivors exceeded 90%. In mixed-effects models that controlled for age, gender, education, and premorbid reading activity, African-Americans scored lower than whites at baseline on a composite measure of global cognition and on specific measures of visuoconstruction and naming. However, they experienced less rapid decline in episodic memory (p < 0.01), with similar but not quite significant effects for global cognition (p = 0.06), perceptual speed (p = 0.07) and naming (p = 0.08). The results suggest that the rate of cognitive decline in AD is slower in African-Americans compared with whites, particularly for episodic memory.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al: Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215–1220.
  2. Wilson RS, Beckett LA, Bennett DA, Albert MS, Evans DA: Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol 1999;56:1274–1279.
  3. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA: Person-specific paths of cognitive decline in Alzheimer’s disease and their relation to age. Psychol Aging 2000;15:18–28.
  4. Hebert LE, Wilson RS, Gilley DW, Beckett LA, Scherr PA, Bennett DA, et al: Decline of language among women and men with Alzheimer’s disease. J Gerontol B Psychol Sci Soc Sci 2000;55:354–360.
  5. Bowler JV, Munoz DG, Merskey H, Hachinski V: Factors affecting the age of onset and rate of progression of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1998;65:184–190.
  6. Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology 1992;42:1689–1696.
  7. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al: A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–396.
  8. Stern Y, Alexander GE, Prohovnik I, Mayeux R: Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease. Ann Neurol 1992;32:371–375.
  9. Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448–460.
  10. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Barnes LL, Evans DA: Premorbid reading activity and patterns of cognitive decline in Alzheimer disease. Arch Neurol 2000;57:1718–1723.
  11. Heyman A, Fillenbaum G, Prosnitz B, Raiford K, Burchett B, Clark C: Estimated prevalence of dementia among elderly black and white community residents. Arch Neurol 1991;48:594–598.
  12. Schoenberg BS, Anderson DW, Haerer AF: Severe dementia. Prevalence and clinical features in a biracial US population. Arch Neurol 1985;42:740–743.
  13. Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, et al: Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49–56.
  14. Gurland BJ, Wilder DE, Lantigua R, Stern Y, Chen J, Killeffer EH, et al: Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry 1999;14:481–493.
  15. Perkins P, Annegers JF, Doody RS, Cooke N, Aday L, Vernon SW: Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology 1997;49:44–50.
  16. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, et al: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein e allele status. Arch Neurol 2003;60:185–189.
  17. Fillenbaum GG, Heyman A, Huber MS, Woodbury MA, Leiss J, Schmader KE, et al: The prevalence and 3-year incidence of dementia in older Black and White community residents. J Clin Epidemiol 1998;51:587–595.
  18. Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, et al: Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004;52:195–204.
  19. Fillenbaum GG, Peterson B, Welsh-Bohmer KA, Kukull WA, Heyman A: Progression of Alzheimer’s disease in black and white patients: the CERAD experience, part XVI. Consortium to Establish a Registry for Alzheimer’s Disease. Neurology 1998;51:154–158.
  20. van Belle G, Uhlmann RF, Hughes JP, Larson EB: Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. J Clin Epidemiol 1990;43:589–595.
  21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  22. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  23. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159–1165.
  24. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH: Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci 1991;57:167–178.
  25. Kimura D: Right temporal-lobe damage. Perception of unfamiliar stimuli after damage. Arch Neurol 1963;8:264–271.
  26. Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O: Contributions to Neuropsychological Assessment, ed 2. New York, Oxford University Press, 1994.
  27. Goodglass H, Kaplan D: The Assessment of Aphasia and Related Disorders, ed 2. Philadelphia, Lea & Febiger, 1983.
  28. Kukull WA: Problems in measuring and interpreting cognitive decline. J Am Geriatr Soc 1998;46:1578–1579.
  29. Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al: Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17:179–193.
  30. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 1982;38:963–974.
  31. SAS Institute Inc: SAS/STAT® User’s Guide, version 8. Cary, SAS Institute Inc, 2000.
  32. Carlson MC, Brandt J, Carson KA, Kawas CH: Lack of relation between race and cognitive test performance in Alzheimer’s disease. Neurology 1998;50:1499–1501.
  33. Fillenbaum GG, Huber M, Taussig IM: Performance of elderly White and African-American community residents on the abbreviated CERAD Boston Naming Test. J Clin Exp Neuropsychol 1997;19:204–210.
  34. Fillenbaum GG, Heyman A, Huber MS, Ganguli M, Unverzagt FW: Performance of elderly African-American and White community residents on the CERAD Neuropsychological Battery. J Int Neuropsychol Soc 2001;7:502–509.
  35. Welsh KA, Fillenbaum G, Wilkinson W, Heyman A, Mohs RC, Stern Y, et al: Neuropsychological test performance in African-American and white patients with Alzheimer’s disease. Neurology 1995;45:2207–2211.
  36. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 2001;49:1148–1155.
  37. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al: The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002;59:1154–1160.
  38. Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, Evans DA, et al: Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003;60:1082–1088.
  39. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661–666.
  40. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.
  41. Schoenberg BS, Anderson DW, Haerer AF: Racial differentials in the prevalence of stroke. Copiah County, Mississippi. Arch Neurol 1986;43:565–568.
  42. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, et al: The APOE-epsilon4 allele and the risk of Alzheimer disease among African-Americans, whites, and Hispanics. JAMA 1998;279:751–755.
  43. Valcour VG, Masaki KH, Curb JD, Blanchette PL: The detection of dementia in the primary care setting. Arch Intern Med 2000;160:2964–2968.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50